Journal: Biomedicines

Article Title: Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin

doi: 10.3390/biomedicines10051190

Figure Lengend Snippet: Expression profiles of genes differentiating the Ishikawa cell line, regardless of the time of incubation with either cisplatin or salinomycin, in comparison with the control.

Article Snippet: We used commercially available kits, such as the beta-Thromboglobulin (beta-TG; CXCL8) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS264511), the mitogen-activated protein kinase 8 ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS9325582), the Nuclear Receptor Related Protein 1 (NURR1; NR4A2) RTU ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS4501531), the cystine/glutamate transporter, SLC7A11, ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS1606069), the ICAM-1 (ICAM-1/CD54) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS2515841), the IL21 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS454439) and the Human CCL7/MCP-3 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS1753914), in accordance with the manufacturers’ recommendations.

Techniques: Expressing, Incubation, Comparison, Control

Journal: Biomedicines

Article Title: Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin

doi: 10.3390/biomedicines10051190

Figure Lengend Snippet: Changes in the expression patterns of genes related to oxidative stress in an Ishikawa cell culture exposed to cisplatin ( A ) and salinomycin ( B ), in comparison to the control obtained via RTqPCR ( p < 0.05). (+)—overexpression in comparison to the control; (−)—downregulated in comparison to the control; C—control; H_12, H_24, H_48—periods of exposure to cisplatin or salinomycin; NR4A2—nuclear receptor subfamily 4 group A member 2; MAP3K8—mitogen-activated protein kinase 8; ICAM1—intercellular adhesion molecule 1; IL21—interleukin 21; CXCL8—C-X-C motif chemokine ligand 8; CCL7—C-C motif chemokine ligand 7; SLC7A11—solute carrier family 7 member 11.

Article Snippet: We used commercially available kits, such as the beta-Thromboglobulin (beta-TG; CXCL8) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS264511), the mitogen-activated protein kinase 8 ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS9325582), the Nuclear Receptor Related Protein 1 (NURR1; NR4A2) RTU ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS4501531), the cystine/glutamate transporter, SLC7A11, ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS1606069), the ICAM-1 (ICAM-1/CD54) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS2515841), the IL21 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS454439) and the Human CCL7/MCP-3 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS1753914), in accordance with the manufacturers’ recommendations.

Techniques: Expressing, Cell Culture, Comparison, Control, Over Expression

Journal: Biomedicines

Article Title: Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin

doi: 10.3390/biomedicines10051190

Figure Lengend Snippet: Results of the one-way ANOVA and post hoc Tukey’s test on RTqPCR results.

Article Snippet: We used commercially available kits, such as the beta-Thromboglobulin (beta-TG; CXCL8) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS264511), the mitogen-activated protein kinase 8 ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS9325582), the Nuclear Receptor Related Protein 1 (NURR1; NR4A2) RTU ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS4501531), the cystine/glutamate transporter, SLC7A11, ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS1606069), the ICAM-1 (ICAM-1/CD54) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS2515841), the IL21 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS454439) and the Human CCL7/MCP-3 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS1753914), in accordance with the manufacturers’ recommendations.

Techniques:

Journal: Biomedicines

Article Title: Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin

doi: 10.3390/biomedicines10051190

Figure Lengend Snippet: Variances in the concentration of the proteins NR4A2, MAP3K8, CXCL8 and SLC7A11 determined via ELISA assay in the Ishikawa cell line regardless of the time of incubation of endometrial cancer cells with either cisplatin ( A ) or salinomycin ( B ), in comparison with the control. C—control; H_12, H_24, H_48—periods of exposure to cisplatin or salinomycin; NR4A2—nuclear receptor subfamily 4 group A member 2; MAP3K8—mitogen-activated protein kinase kinase 8; CXCL8—C-X-C motif chemokine ligand 8; SLC7A11—solute carrier family 7 member 11; p — p -value.

Article Snippet: We used commercially available kits, such as the beta-Thromboglobulin (beta-TG; CXCL8) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS264511), the mitogen-activated protein kinase 8 ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS9325582), the Nuclear Receptor Related Protein 1 (NURR1; NR4A2) RTU ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS4501531), the cystine/glutamate transporter, SLC7A11, ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS1606069), the ICAM-1 (ICAM-1/CD54) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS2515841), the IL21 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS454439) and the Human CCL7/MCP-3 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS1753914), in accordance with the manufacturers’ recommendations.

Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay, Incubation, Comparison, Control

Journal: Biomedicines

Article Title: Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin

doi: 10.3390/biomedicines10051190

Figure Lengend Snippet: Results of the one-way ANOVA and post hoc Tukey’s test for ELISA results.

Article Snippet: We used commercially available kits, such as the beta-Thromboglobulin (beta-TG; CXCL8) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS264511), the mitogen-activated protein kinase 8 ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS9325582), the Nuclear Receptor Related Protein 1 (NURR1; NR4A2) RTU ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS4501531), the cystine/glutamate transporter, SLC7A11, ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS1606069), the ICAM-1 (ICAM-1/CD54) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS2515841), the IL21 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS454439) and the Human CCL7/MCP-3 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS1753914), in accordance with the manufacturers’ recommendations.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Biomedicines

Article Title: Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin

doi: 10.3390/biomedicines10051190

Figure Lengend Snippet: Signaling pathways modulated by genes related to the phenomenon of oxidative stress in Ishikawa cells exposed to cisplatin or salinomycin.

Article Snippet: We used commercially available kits, such as the beta-Thromboglobulin (beta-TG; CXCL8) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS264511), the mitogen-activated protein kinase 8 ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS9325582), the Nuclear Receptor Related Protein 1 (NURR1; NR4A2) RTU ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS4501531), the cystine/glutamate transporter, SLC7A11, ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS1606069), the ICAM-1 (ICAM-1/CD54) ELISA Kit (MyBioSource, Inc., San Diego, CA, USA, 92195-3308; Catalog number MBS2515841), the IL21 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS454439) and the Human CCL7/MCP-3 ELISA Kit (MyBioSource, Inc. San Diego, CA, USA, 92195-3308; Catalog number MBS1753914), in accordance with the manufacturers’ recommendations.

Techniques: Protein-Protein interactions, Coagulation, Activation Assay

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: IL-21-treated naive CD45RA + CD8 + T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype

doi: 10.1007/s00262-010-0936-8

Figure Lengend Snippet: IL-21 promotes the generation of AML-reactive CD8+ T cells from naive CD45RA+ precursors. a Numbers of AML-reactive cultures per 96 replicate wells obtained with purified CD45RA+ CD8+ T cells or unseparated CD8+ T cells in three AML patient/donor pairs with full HLA-class I match. Allogeneic mini-MLLCs were initiated with (10 or 30 ng/mL) or without IL-21, respectively, and were analyzed 5 days after the second (d14) or third (d21) antigen-specific restimulation for reactivity to primary AML blasts in split-well IFN-γ ELISpot assay. Wells considered as “positive” for AML recognition had ≥5-fold higher spot numbers compared to background level (i.e. spontaneous IFN-γ production). b Numbers of AML-reactive mini-cultures per 96 replicate wells generated from naive CD45RA+ CD8+ T cells from seven HLA-class I-matched AML patient/donor pairs

Article Snippet: To analyze the impact of IL-21 in side-by-side MLLCs, the cytokine was added at 10–30 ng/mL (Biomol, Hamburg, Germany) or omitted, respectively.

Techniques: Purification, Enzyme-linked Immunospot, Generated

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: IL-21-treated naive CD45RA + CD8 + T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype

doi: 10.1007/s00262-010-0936-8

Figure Lengend Snippet: HLA-class I restriction, cross-reactivity, in vitro expansion, and TCR Vβ chains of AML-reactive CD8+ T-cell populations. Shown are three representative CTL clones from three different AML patient/donor pairs. a CTL 2D8 (MZ201-AML/Don.168) recognizing exclusively patient’s AML blasts, b CTL 5H11 (MZ580-AML/Don.931) reacting to patient’s AML blasts as well as patient-derived lymphocytes, c CTL 7H1 (MZ529-AML/Don.730) recognizing patient’s hematopoietic as well as non-hematopoietic cells. Left panel cross-reactivity patterns to patient’s hematopoietic cells and stromal fibroblasts as well as donor’s hematopoietic cells and the natural killer cell-target K562 determined by IFN-γ ELISpot assay. Note that anti-HLA-class I mAb W6/32 inhibited recognition of AML blasts. Cross-reactivity to fibroblasts, PHA-activated T-cell blasts, and donor PBMCs was defined as significant if values were >10% of AML reactivity. Middle panel mini-MLLCs were initiated with 104 naive CD45RA+ CD8+ T cells and were stimulated once a week with irradiated AML blasts. Numbers of expanding cells were weekly determined as soon as cell counting was feasible (mostly d28–d35). Right panel flow cytometric characterization of the TCR Vβ chain used by the CTLs that grew out of mini-MLLCs. CTL was defined as monoclonal if >90% of cells expressed a single TCR Vβ chain. *CTL 5H11 cross-reacts with AML blasts from patient MZ946. Because bone marrow aspirate from patient MZ580 (whose AML cells were used for stimulation) was not available, stromal fibroblasts isolated from patient MZ946 were used

Article Snippet: To analyze the impact of IL-21 in side-by-side MLLCs, the cytokine was added at 10–30 ng/mL (Biomol, Hamburg, Germany) or omitted, respectively.

Techniques: In Vitro, Clone Assay, Derivative Assay, Enzyme-linked Immunospot, Irradiation, Cell Counting, Isolation